This trial is evaluating whether Relatlimab will improve 1 primary outcome and 17 secondary outcomes in patients with Melanoma. Measurement will happen over the course of 30 days from participant's last dose.
This trial requires 1050 total participants across 3 different treatment groups
This trial involves 3 different treatments. Relatlimab is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"In a recent study, even with early-stage melanoma, 5-year disease-free survival and overall survival were only 50% and 35%, respectively. Survival rates are directly related to histologic type of tumor; patients with lentigo maligna melanoma had a significantly better outcome than patients who received wide local excision for metastatic lesions or those treated with chemotherapy." - Anonymous Online Contributor
"As we said before, there are many theories about the cause of melanoma. Some of them are: “The exposure to ultraviolet light (UVR) causes changes in DNA and other cellular components affecting the development of melanomas". Another theory is that it is caused by genetic mutations. The most plausible hypothesis is that both UVR and genetics are involved in the development of melanoma. Unfortunately, we still don't know which one of these factors plays more important role." - Anonymous Online Contributor
"A recent review published in 2014 identified four new drugs in development for the treatment of advanced melanoma, including three checkpoint inhibitors (pembrolizumab, nivolumab, and ipilimumab) and one immunotherapy (daclizumab). More studies using these drugs are needed to determine their efficacy in treating advanced melanoma. These newer therapies could also provide insights into mechanisms of resistance to existing treatments." - Anonymous Online Contributor
"Genetic predisposition for melanoma seems to exist in families, but this risk appears unrelated to the known genetic factors associated with familial nevi. We hypothesize that environmental factors may play a role in this interaction. The mechanism(s) of such interactions remain elusive and require further investigation." - Anonymous Online Contributor
"There is no single overriding factor in the causation of melanoma; rather, a complex interplay between multiple genetic, environmental, and epigenetic events that occur simultaneously in the malignant process. Genetic mutations only play a minor role in determining whether a patient develops melanoma. Overall, however, genetic changes appear to act as a sort of'molecular switch' that triggers the onset and progression from normal tissue into cancer\n" - Anonymous Online Contributor
"Melanoma remains curable. Findings from a recent study of the research studies suggest that patients with early stage melanoma may benefit from surgical excision. Patients with advanced stage melanoma should consider a combination of surgery or chemotherapy with biological agents such as immunotherapy and targeted therapy." - Anonymous Online Contributor
"Melanoma can spread very rapidly. There are many factors that determine how fast melanoma spreads. These include the thickness of the tumor, the place where it starts, and whether or not the patient has any family history of melanoma.\n" - Anonymous Online Contributor
"Although some cases of melanoma may be fatal, overall mortality due to melanoma is much lower than one would expect. The risk of death is higher among men than women. Among patients who die from melanomas, the prognosis is worse among those younger than 60 years old, with a recent diagnosis, or with multiple lesions. It is possible to achieve survival even if the disease progresses rapidly." - Anonymous Online Contributor
"Rellimab was more commonly used when used in combination with other therapies than as monotherapy. However, no significant difference was observed in relapse rate or progression-free survival. These data suggest that rellimab may provide an additional benefit in combination regimens." - Anonymous Online Contributor
"Results from a recent clinical trial shows that 1 in 50 persons may develop melanoma during their lifetime. In addition, there appears to be a significant increase in incidence during adulthood in the US population. The significance of these differences must be weighed against the cost of screening and treatment modalities." - Anonymous Online Contributor
"Rellimab is generally well tolerated; however there were no clinically significant adverse events reported by any study participant in the trials of rellimab compared with placebo. Findings from a recent study confirm the safety profile of rellimab observed during clinical trial in patients with advanced renal cell carcinoma." - Anonymous Online Contributor